BioCentury
ARTICLE | Company News

Cancer Research UK and Merck KGaA extend 2015 deal to discover Hippo-YAP pathway therapies

July 14, 2017 7:09 PM UTC

The Cancer Research Technology (CRT) commercial arm of Cancer Research UK (London, U.K.) said it extended a 2015 deal with Merck KGaA (Xetra:MRK) to discover cancer treatments targeting the Hippo-yes-associated protein 1 (YAP1; YAP) signaling pathway...